Brenus Pharma's STC-1010 Shows Promise in Metastatic Colorectal Cancer
Brenus Pharma has announced promising first-in-human data for its lead candidate, STC-1010, at the AACR Annual Meeting 2026. STC-1010 is a next-generation in vivo allogeneic immunotherapy built on Stimulated Ghost Cells (SGC) technology, aimed at treating microsatellite-stable colorectal cancer (MSS CRC), a setting resistant to standard immunotherapy. The Phase I/IIa trial, BreAK CRC001, evaluated STC-1010 in unresectable metastatic MSS CRC patients, showing favorable safety with no dose-limiting toxicities and a 100% disease control rate. The trial also demonstrated evidence of immune activation, including delayed-type hypersensitivity responses. These results support the continued advancement of STC-1010 toward later-stage evaluation and validate the SGC technology as a scalable approach for high unmet-need solid tumors. 
